Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
Resource Type
Article
Authors
Lu, Shun ; Zhang, Yiping ; Zhang, Guojun ; Zhou, Jianying ; Cang, Shundong ; Cheng, Ying ; Wu, Gang ; Cao, Peiguo ; Lv, Dongqing ; Jian, Hong ; Chen, Chengshui ; Jin, Xiangming ; Tian, Panwen ; Wang, Kai ; Jiang, Guanming ; Chen, Gongyan ; Chen, Qun ; Zhao, Hui ; Ding, Cuimin ; Guo, Renhua ; Sun, Guoping ; Wang, Bin ; Jiang, Liyan ; Liu, Zhe ; Fang, Jian ; Yang, Junquan ; Zhuang, Wu ; Liu, Yunpeng ; Zhang, Jian ; Pan, Yueyin ; Chen, Jun ; Yu, Qitao ; Zhao, Min ; Cui, Jiuwei ; Li, Dianming ; Yi, Tienan ; Yu, Zhuang ; Yang, Yan ; Zhang, Yan ; Zhi, Xiuyi ; Huang, Yunchao ; Wu, Rong ; Chen, Liangan ; Zang, Aimin ; Cao, Lejie ; Li, Qingshan ; Li, Xiaoling ; Song, Yong ; Wang, Donglin ; Zhang, Shucai ; Ding, Lieming ; Zhang, Ling ; Yuan, Xiaobin ; Yao, Lin ; Shen, Zhilin
Source
In Journal of Thoracic Oncology October 2022 17(10):1192-1204
Subject
Language
ISSN
1556-0864